Tersera Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TERSERA
TERSERA has six approved drugs.
There are fourteen US patents protecting TERSERA drugs.
There are two hundred and fifteen patent family members on TERSERA drugs in thirty-eight countries and thirty-nine supplementary protection certificates in eighteen countries.
Summary for Tersera
| International Patents: | 215 |
| US Patents: | 14 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 6 |
Drugs and US Patents for Tersera
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tersera | VARUBI | rolapitant hydrochloride | TABLET;ORAL | 206500-001 | Sep 1, 2015 | RX | Yes | Yes | 7,049,320 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Tersera | VARUBI | rolapitant hydrochloride | TABLET;ORAL | 206500-001 | Sep 1, 2015 | RX | Yes | Yes | 7,563,801 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Tersera | VARUBI | rolapitant hydrochloride | EMULSION;INTRAVENOUS | 208399-001 | Oct 25, 2017 | DISCN | Yes | No | 8,404,702 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Tersera
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Tersera | VARUBI | rolapitant hydrochloride | TABLET;ORAL | 206500-001 | Sep 1, 2015 | 8,796,299 | ⤷ Start Trial |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | 7,118,552 | ⤷ Start Trial |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | 5,366,734 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Tersera Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 5640065 | ⤷ Start Trial |
| European Patent Office | 2004148 | ⤷ Start Trial |
| Portugal | 2203444 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tersera Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1463716 | PA2017032,C1463716 | Lithuania | ⤷ Start Trial | PRODUCT NAME: ROLAPITANTAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOS, ISKAITANT ROLAPITANTO HIDROCHLORIDO MONOHIDRATA; REGISTRATION NO/DATE: EU/1/17/1180/001 20170420 |
| 1463716 | C201730043 | Spain | ⤷ Start Trial | PRODUCT NAME: ROLAPITANT, OPCIONALMENTE EN FORMA DE UNA SAL FARMACEUTICAMENTE ACEPTABLE, INCLUYENDO ROLAPITANT CLORHIDRATO MONOHIDRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1180; DATE OF AUTHORISATION: 20170420; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1180; DATE OF FIRST AUTHORISATION IN EEA: 20170420 |
| 2004646 | C201730041 | Spain | ⤷ Start Trial | PRODUCT NAME: ROLAPITANT CLORHIDRATO MONOHIDRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1180; DATE OF AUTHORISATION: 20170420; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1180; DATE OF FIRST AUTHORISATION IN EEA: 20170420 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
